Calif. biotech gets $13.5M funding boost

05/7/2013 | American City Business Journals

NGM Biopharmaceuticals secured almost $13.5 million in an equity offering targeted at $50 million, a securities filing showed. Rather than betting on a single drug, NGM is using a basic-science approach to uncover how genes, hormones and receptors regulate diabetes, obesity and other cardiometabolic disorders. The company hopes to develop a treatment that mimics the benefits of gastric bypass surgery, which has been shown to improve type 2 diabetes outcomes even before weight loss begins.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC